Added to YB: 2026-09-15
Pitch date: 2026-09-11
NRXP [neutral]
NRx Pharmaceuticals, Inc.
+3.56%
current return
Author Info
No bio for this author
Company Info
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States.
Market Cap
$147.1M
Pitch Price
$3.37
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.22
P/E
-4.38
EV/Sales
35.72
Sector
Pharmaceuticals
Category
special_situation
Biotech Conference coverage day 4 session 1 - NRx Pharmaceuticals, Inc.
NRXP (quick overview): NRx is building a vertically integrated depression platform around preservative-free ketamine, NRX-101 and precision TMS clinics. Management expects an FDA decision around mid-October; the thesis is that approval and commercial launch could improve reimbursement and generate cash to fund NRX-101 Phase 3. At roughly $3.40, commercial success offers substantial upside, but the thesis requires meaningful hospital demand and carries FDA, manufacturing, reimbursement, clinical-development and clinic-operating risks.
Read full article (2 min)